Study identifies new potential treatment option for triple negative breast cancer

May 21, 2018, Mayo Clinic
Study identifies new potential treatment option for triple negative breast cancer
Credit: Mayo Clinic

In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.

In this study, Mayo investigators identified that the drug 5-aza-2'-deoxycytidine (decitabine) which is FDA approved for the treatment of certain hematological (blood) cancers, could significantly inhibit the growth of triple-negative cancers, and importantly this effect was also seen in tumors resistant to chemotherapy. This response was dependent on the presence of certain critical proteins called DNA methyl transferase proteins that are present in only a subset of triple negative breast cancers. This provides a way to identify which patients could benefit from this therapy.

"There is a great need to identify additional treatment options for , which is one of the most difficult to treat subtypes of breast ," says Mayo researcher Liewei Wang, M.D., Ph.D. "The study is a demonstration that we can take advantage of many existing FDA approved drugs to expand their usage by better understanding the mechanisms of how they work and applying them to other cancers."

This study was part of the ongoing work from the Breast Cancer Genome-Guided Therapy (BEAUTY) study, co-led by Matthew Goetz, M.D., a Mayo medical oncologist and Judy Boughey, M.D., a Mayo breast surgeon. The BEAUTY study generated patient derived xenografts (immortalizing breast tumor cells) from patients with breast cancer treated with chemotherapy.

"Patients whose tumor does not respond well to chemotherapy are known to be at significantly increased risk of and death," says Dr. Boughey. "Therefore our focus is to identify new treatment options for these ."

In the living xenografts from BEAUTY, Mayo investigators found that when DNA methyl transferase proteins were present, decitabine showed an effect in triple-negative breast cancer at a low therapeutic dose. The low doses would result in less toxicity and might allow the drug to be used for a longer time, all of which might help to achieve greater therapeutic efficacy.

According to Dr. Goetz, plans are underway to prospectively study the impact of decitabine in a prospective clinical trial, called BEAUTY2, which is focused on women with triple negative that is resistant to chemotherapy.

Explore further: Researchers identify new potential treatment for cancer metastasis

Related Stories

Researchers identify new potential treatment for cancer metastasis

January 9, 2017
Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the U.S. Food and Drug Administration.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Team targets tumor suppressor to treat 'triple-negative' breast cancer

February 5, 2018
A study by scientists at the University of Arizona Cancer Center and Cancer Research UK has found that the loss of a specific tumor suppressor in "triple-negative" breast cancer provides clues about potential new approaches ...

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

Breast cancer study provides critical information on tumor sequencing and chemother

March 10, 2017
Tumor sequencing is increasingly used to select treatment for patients with cancer, but its role in women with newly diagnosed breast cancer is unknown. Mayo Clinic researchers reported today in the Journal of the National ...

Researchers identify potential therapeutic target in aggressive breast cancer cells

November 15, 2017
An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research published on the cover of Oncotarget. The findings ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.